Search results for: johnson

July 8th, 2011

JNJBTW Follow Friday

As we get ready for the weekend, what better way to spend a summer Friday on JNJBTW than to take a look at what’s going on at the other Johnson & Johnson social media sites.

The 2010 Johnson & Johnson contributions report is out, and is available online at this link.

The featured homepage stories on this week are drawn from the contributions report.  Recycling Materials and Shaping Lives follows one of the catadors at The recycling cooperative Futura in São José dos Campos, Brazil.  A catador is a person who lives and works in a cooperative, collecting and processing waste material for recycling.  These cooperatives provide employment, a level of dignity and a purpose-filled way of life for their members, and they are becoming key suppliers of recycled materials to businesses.  Keeping Children Warm and Safe tells the story of some Johnson & Johnson Family of Companies employees and their colleagues who volunteer their time to make blankets for children affected by humanitarian disasters as part of the One Child, One Blanket program. (By the way, employees finding a way to make a personal contribution to help after disasters is a tradition that goes back to 1906 at Johnson & Johnson.) Resuscitation Saves Tens of Thousands of Newborns in China profiles China’s Neonatal Resuscitation Program (NRP), a joint effort by Johnson & Johnson, the Chinese Ministry of Health and the American Academy of Pediatrics to address birth asphyxia—when a baby is unable to breathe at birth.

Read More

June 29th, 2011

2011 Dr. Paul Janssen Award for Biomedical Research Honors Biotechnology Pioneer

By Paul Stoffels, Worldwide Chairman, Pharmaceuticals, Johnson & Johnson

Biotechnology has come a long way since the discovery of recombinant DNA almost 40 years ago and the sequencing of the human genome a decade ago.  Today, the term has a broader definition: biomarkers, antibodies, genomics, protemics, RNA, novel scaffolds, peptides, cell therapies, and more, all to help us solve the most important diseases of our time. One example of such an advance is the treatment of angiogenesis, the process of new blood vessel formation that plays a key role in cancer proliferation and a number of other diseases.  These treatments have improved the lives of millions of patients.

Dr. Napoleone Ferrara, Genentech Fellow, has been influential in the development of anti-angiogenesis treatments. Through the identification of a human vascular endothelial cell growth factor (VEGF), he discovered there may be a ways to control the blood supply to particular parts of the body. His innovative work on angiogenesis opened the door to the development of a new class of therapeutics to combat a serious eye disorder and contributed to the development of new oncology therapeutics.

Today Johnson & Johnson honored Dr. Napoleone Ferrara with the 2011 Dr. Paul Janssen Award for Biomedical Research, an award that recognizes passionate and creative scientists like Dr.

Read More

June 28th, 2011

Response to Recent Coverage in the Financial Times

Today’s Financial Times included a story (subscription required) about Johnson & Johnson’s comprehensive approach to preventing and treating disease. The story contained a number of inaccuracies, which Johnson & Johnson addressed in a letter to the Financial Times editors. Here is what we had to say.

Dear Editor of the Financial Times:

Today’s Financial Times included an article about the comprehensive approach of Johnson & Johnson to the prevention and treatment of significant chronic diseases. The story contained a number of inaccuracies.

While Johnson & Johnson believes the breadth of its business interests across consumer, diagnostics and pharmaceuticals business segments is a valuable advantage in its approach to the treatment of a number of chronic conditions, including cancer, the company does not intend to market consumer and regulated products more closely, as reported. In a discussion with the Financial Times, company executives talked about how leaders from the various business segments share insights that improve their understanding of the needs of patients with cancer and other conditions, and, presumably, result in products and services that better meet these needs. They did not, however, state or suggest that the company would market such products together.


Bill Price
Vice President, Media Relations
Johnson & Johnson

Read More

June 23rd, 2011

Partnering for a Healthier World

From Paul Stoffels, Worldwide Chairman, Pharmaceuticals, Johnson & Johnson

This week, a team from Johnson & Johnson joined other world leaders at the Pacific Health Summit to discuss an important and timely topic: vaccines.

Johnson & Johnson made a commitment to vaccines through its recent acquisition of Crucell N.V., a company that is passionate about innovation and about meeting the public health demand for vaccines for children in the world’s poorest countries.

Crucell specializes in the research and development of innovative vaccines especially for infectious diseases that devastate families in the developing world.  The company has a track-record for innovation and is passionate about delivering high quality and easy to use vaccines consistently, quickly and at the lowest possible prices in developing markets. 

One of their most important products is Quinvaxem® a single-dose, fully-liquid vaccine, developed specifically for use in developing countries. As a pentavalent vaccine, it offers protection against five of the world’s most prevalent childhood diseases– Hepatitis-B, Haemophilus influenzae type B (Hib), Diphtheria, Tetanus and Pertussis. Since its launch, more than 200 million doses have been distributed worldwide, meaning that more than 60 million children in many of the poorest countries in the world have been fully vaccinated. It is becoming the cornerstone of UNICEF’s childhood vaccine program.  

Read More

June 9th, 2011

Ortho Clinical Diagnostics: A Culture of Health

From Nick Valeriani, Company Group Chairman, Ortho Clinical Diagnostics

For more than two years, I’ve been lucky enough to lead a company that I believe exemplifies the Johnson & Johnson ideal of a culture of health. My colleagues and I have been working together to help our employees live our franchise vision: enabling people to be healthier, feel better and live longer. Our vision represents the individual strengths of the three companies within our franchise: Ortho Clinical Diagnostics, Therakos and Veridex. It also brings us together to focus on what matters most – our employees and the people we serve.

Our vision started with our employees’ recognition of the extraordinary value of diagnostics throughout the health care continuum. We work to cultivate an environment where we focus on the benefits of using health information – such as diagnostic tests – to stay healthy and well, and we feel that this should be demonstrated not only in the work that we do, but in our personal lives as well. For example, we talk about the ways in which our products can provide information that’s vital to preserving wellness, as well as managing disease; by offering health and wellness-related educational seminars and programs; by sharing success stories from patients and employees who benefit from our products; and by encouraging employees to evaluate their lifestyles and make small and simple changes for better health.

Read More

June 2nd, 2011

Extending the Benefits of HIV Treatment

From Paul Stoffels, Worldwide Chairman, Pharmaceuticals, Johnson & Johnson

 Extending the benefits of HIV treatment throughout the world is a passion of mine.  As the Worldwide Chairman of Pharmaceuticals for Johnson & Johnson, I’ve been able to see the progress we’ve made in combating this disease over the past few decades. June 5 marks the 30th anniversary of the first report by the U.S. Centers for Disease Control of a disease we would later come to know as HIV.  During those early years of the epidemic, contracting HIV meant a two-year life expectancy. Today, in the western world, HIV has become a chronic condition that can be managed through modern medicine.

Yet, meeting the individual treatment needs of the estimated 33.3 million people living with HIV throughout the world remains an extraordinary challenge.  Our company’s ongoing commitment to addressing this challenge traces all the way back to work in the laboratories of Dr. Paul Janssen.  On Friday, May 20, we reported on a major milestone in these efforts.

As a company, we are also expanding the benefits of our HIV drugs to the developing world.  We have agreements in place with generic manufactures to produce them for sub-Saharan Africa and India

Read More

June 1st, 2011

National Employee Wellness Month

From Dr. Fikry Isaac MD, MPH, Vice President Global Health Services, Johnson & Johnson

As part of my role within the Johnson & Johnson Global Health services organization, I have been privileged with the opportunity to lead our company’s efforts to improve the health and well-being of our employees around the world.  At Johnson & Johnson we understand that an investment in the health of our employees is an investment in the health of our company, which is why I’m glad to announce our proud support for National Employee Wellness Month.  This annual initiative, sponsored by the Partnership to Fight Chronic Disease, Virgin Health Miles and Stop Obesity Alliance, and supported by nearly 100 other companies, helps business leaders share and develop successful strategies for the prevention of chronic disease and maintenance of good health for employees.  Throughout our 125 year history we’ve led the way in our commitment to the health of our employees and we are happy to support an initiative that will help foster a culture of health in other companies.

While a focus on a healthy and productive workforce has long been a hallmark of our company, Johnson & Johnson’s commitment to employee health and wellness began officially with former Chairman James Burke’s pledge to make the employees of Johnson & Johnson’s Family of Companies the healthiest in the world. 

Read More

May 27th, 2011

Yesterday’s Pharmaceutical Business Review

Yesterday, we held a meeting with the investment community to review growth strategies for Johnson & Johnson’s pharmaceuticals business.   It was an in-depth look at how our employees and partners across the world are working to address major unmet needs in a number of areas, and developing an amazing pipeline of new medicines.   Sheri McCoy, vice chairman of the Executive Committee, spoke about meeting needs with science and increasing the capacity to treat patients, saying , “We have the opportunity to make a difference for people around the world.”

Paul Stoffels, M.D., also provided an overview of the strength of the pharmaceuticals pipeline, and Joaquin Duato reviewed the commercial strategies that have enabled our pharmaceuticals businesses to become launch leaders in several categories.  Paul and Joaquin are both Worldwide Chairmen, Pharmaceuticals.  The Company highlighted the expectations of its pharmaceuticals businesses to file 11 new products and more than 30 line extensions in the next five years.  

The R&D leaders took investors on a deeper dive in five therapeutic areas:  neuroscience, cardiovascular and metabolism, immunology, oncology and infectious diseases and vaccines.   They spoke about recent product approvals, the strength of the pharmaceuticals pipeline in these areas, and the geographic reach of the business, both in established markets and in emerging markets.   

Read More

May 25th, 2011

A classroom is a classroom…?

From Michael Bzdak, Ph.D., Director, Johnson & Johnson Corporate Contributions

As part of my work in global philanthropy, I occasionally have the privilege to visit some of our partners to experience their reality and to understand their challenges.  A couple of weeks ago, a small group from Johnson & Johnson spent a few hours at Nyumbani Village in rural Kenya. Nyumbani Village is a self-sustaining community designed to serve orphans and adults who have been affected by the HIV pandemic.  The Village, a three-hour drive from Nairobi, provides a family-like setting for orphaned children under the care of elderly adults. According to their web site, the Village seeks “to ensure that the children receive love, sustenance, health-care, holistic education and culture transfer, aiming at their physical, psychosocial and spiritual development, and, at the same time, providing holistic care and support for the grandparents in their later years.”

In advance of our visit,  I made a request to spend some time in the classroom (see above photo). I was thrilled to be able to teach in the equivalent of a ninth-grade English class where the students were learning the nuances of the English language.  Although a far cry from the “smart classrooms” of our New Jersey schools, the classroom at Nyumbani was a simple but powerful learning environment. 

Read More

May 19th, 2011

EARTHWARDS (TM): Moving toward a Healthy Future – Continuous Greener Improvements on Our Products

From Ann Lee-Jeffs, Manager, Worldwide Environmental Health & Safety Research & Development, Johnson & Johnson

As a product steward at Johnson & Johnson, I’m constantly thinking about the environmental impact of products whether I’m shopping at the mall or picking up groceries at the supermarket. It’s more than just my job – it’s become a part of my life.

At Johnson & Johnson, we recognize the importance of caring for the environment as do our consumers. Given this, in 2009, Johnson & Johnson introduced EARTHWARDS™, a process that helps the product teams at our operating companies assess the environmental and social impacts across a product’s full life cycle and the work to reduce those impacts. The process also celebrates greener product successes, and enables brand teams to evaluate potential environmental claims with a clear set of information.

To be considered for EARTHWARDS™ designation, a product must achieve a greater than 10 percent improvement in at least three of the seven areas below:

  • Materials used
  • Packaging reduction
  • Energy reduction
  • Waste reduction
  • Water reduction
  • Positive social impact or benefit
  • Product innovation

To evaluate each of these areas, a proprietary scorecard was developed in 2009, in partnership with a leading sustainability and product stewardship consulting firm using information from stakeholder interviews and best practices from other leading companies.

Read More